Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
Bio-Gene Technology Ltd. engages in the research and development of the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. Its novel platform technology is based on occurring beta-triketones, a type of chemistry that may offer solutions for insect management control in animal health and crop protection as well as in public health applications. The company was founded on November 8, 1995 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.09
Trade Value (12mth)
AU$980.00
1 week
4.55%
1 month
-2.13%
YTD
-22.03%
1 year
-50.54%
All time high
0.35
EPS 3 yr Growth
-25.70%
EBITDA Margin
%
Operating Cashflow
-$3m
Free Cash Flow Return
-91.60%
ROIC
-80.10%
Interest Coverage
N/A
Quick Ratio
8.50
Shares on Issue (Fully Dilluted)
178m
HALO Sector
Industrials
Next Company Report Date
21-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
06 September 24 |
Gene Technology Ltd. - Investor Webinar Presentation 06 Sep 24
×
Gene Technology Ltd. - Investor Webinar Presentation 06 Sep 24 |
02 September 24 |
Gene Technology Ltd. - Investor Webinar - Shareholder update 06 SEP 24
×
Gene Technology Ltd. - Investor Webinar - Shareholder update 06 SEP 24 |
28 August 24 |
Gene Technology Ltd. - Appendix 4E and 2024 Annual Report
×
Gene Technology Ltd. - Appendix 4E and 2024 Annual Report |
28 August 24 |
Gene Technology Ltd. - Appendix 4G and 2024 Corporate Governance Statement
×
Gene Technology Ltd. - Appendix 4G and 2024 Corporate Governance Statement |
14 August 24 |
Gene Technology Ltd. - Envu collaboration on Flavocide for mosquito management
×
Gene Technology Ltd. - Envu collaboration on Flavocide for mosquito management |
08 August 24 |
Gene Technology Ltd. - APVMA Pre Application Assistance
×
Gene Technology Ltd. - APVMA Pre Application Assistance |
30 July 24 |
Gene Technology Ltd. - Quarterly Activities/Appendix 4C Cash Flow Report
×
Gene Technology Ltd. - Quarterly Activities/Appendix 4C Cash Flow Report |
17 May 24 |
Gene Technology Ltd. - Company Secretary Appointment/Resignation
×
Gene Technology Ltd. - Company Secretary Appointment/Resignation |
06 May 24 |
Gene Technology Ltd. - Notification of cessation of securities - BGT
×
Gene Technology Ltd. - Notification of cessation of securities - BGT |
29 April 24 |
Gene Technology Ltd. - Quarterly Activities/Appendix 4C Cash Flow Report
×
Gene Technology Ltd. - Quarterly Activities/Appendix 4C Cash Flow Report |
08 April 24 |
Gene Technology Ltd. - Appointment of CFO and Joint Company Secretary
×
Gene Technology Ltd. - Appointment of CFO and Joint Company Secretary |
05 March 24 |
Gene Technology Ltd. - Investor Webinar - FY24 Half Year Review
×
Gene Technology Ltd. - Investor Webinar - FY24 Half Year Review |
26 February 24 |
Gene Technology Ltd. - Appendix 4D - Half Year Accounts - 31 December 2023
×
Gene Technology Ltd. - Appendix 4D - Half Year Accounts - 31 December 2023 |
29 January 24 |
Gene Technology Ltd. - Appendix 4C - 31 December 2023
×
Gene Technology Ltd. - Appendix 4C - 31 December 2023 |
19 January 24 |
Gene Technology Ltd. - Bio-Gene Receives R&D Tax Incentive
×
Gene Technology Ltd. - Bio-Gene Receives R&D Tax Incentive |
13 December 23 |
Gene Technology Ltd. - BGT Corporate Presentation
×
Gene Technology Ltd. - BGT Corporate Presentation |
13 December 23 |
Gene Technology Ltd. - Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan
×
Gene Technology Ltd. - Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan |
07 December 23 |
Gene Technology Ltd. - Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan
×
Gene Technology Ltd. - Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan |
01 December 23 |
Gene Technology Ltd. - Bio-Gene to Present at Automic Invest 2023 Conference
×
Gene Technology Ltd. - Bio-Gene to Present at Automic Invest 2023 Conference |
27 November 23 |
Gene Technology Ltd. - Becoming a substantial holder
×
Gene Technology Ltd. - Becoming a substantial holder |
23 November 23 |
Gene Technology Ltd. - BGT 2023AGM - Chairman's Address
×
Gene Technology Ltd. - BGT 2023AGM - Chairman's Address |
23 November 23 |
Gene Technology Ltd. - BGT 2023AGM - CEO's Address
×
Gene Technology Ltd. - BGT 2023AGM - CEO's Address |
23 November 23 |
Gene Technology Ltd. - BGT 2023AGM - CEO's Presentation
×
Gene Technology Ltd. - BGT 2023AGM - CEO's Presentation |
23 November 23 |
Gene Technology Ltd. - Results of Meeting
×
Gene Technology Ltd. - Results of Meeting |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.